Suppr超能文献

相似文献

1
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
Oncogene. 2015 Jan 8;34(2):257-62. doi: 10.1038/onc.2013.541. Epub 2013 Dec 23.
2
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
Oncogene. 2017 Jul 20;36(29):4150-4160. doi: 10.1038/onc.2017.44. Epub 2017 Mar 20.
3
A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.
4
MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.
PLoS One. 2017 May 18;12(5):e0178028. doi: 10.1371/journal.pone.0178028. eCollection 2017.
5
Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Oncotarget. 2016 Apr 26;7(17):24125-40. doi: 10.18632/oncotarget.8214.
7
Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Oncogene. 2013 Oct 17;32(42):5089-100. doi: 10.1038/onc.2012.525. Epub 2012 Nov 26.
8
The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
Expert Opin Ther Targets. 2017 Nov;21(11):997-999. doi: 10.1080/14728222.2017.1391791. Epub 2017 Oct 13.

引用本文的文献

1
The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors.
Int J Mol Sci. 2025 May 17;26(10):4814. doi: 10.3390/ijms26104814.
2
Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis.
Mol Oncol. 2025 Apr;19(4):1002-1028. doi: 10.1002/1878-0261.13788. Epub 2025 Jan 5.
3
A novel histone acetylation-associated gene signature with prognostic value in Ewing sarcoma.
Discov Oncol. 2024 Dec 30;15(1):848. doi: 10.1007/s12672-024-01689-4.
4
Unlocking epigenetics for precision treatment of Ewing's sarcoma.
Chin J Cancer Res. 2024 Jun 30;36(3):322-340. doi: 10.21147/j.issn.1000-9604.2024.03.08.
5
Histone Demethylase KDM3 (JMJD1) in Transcriptional Regulation and Cancer Progression.
Adv Exp Med Biol. 2023;1433:69-86. doi: 10.1007/978-3-031-38176-8_4.
6
Fli1 and Tissue Fibrosis in Various Diseases.
Int J Mol Sci. 2023 Jan 18;24(3):1881. doi: 10.3390/ijms24031881.
7
An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22.
Cancers (Basel). 2022 Dec 19;14(24):6255. doi: 10.3390/cancers14246255.
10
Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.
Biomedicines. 2022 Jun 5;10(6):1325. doi: 10.3390/biomedicines10061325.

本文引用的文献

1
The role of miRNAs in regulating gene expression networks.
J Mol Biol. 2013 Oct 9;425(19):3582-600. doi: 10.1016/j.jmb.2013.03.007. Epub 2013 Mar 13.
2
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.
Mol Cancer Ther. 2012 Dec;11(12):2556-65. doi: 10.1158/1535-7163.MCT-12-0463. Epub 2012 Oct 16.
3
MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Oncogene. 2013 Aug 15;32(33):3915-21. doi: 10.1038/onc.2012.403.
4
Molecular biology. Genetic events that shape the cancer epigenome.
Science. 2012 Jun 22;336(6088):1513-4. doi: 10.1126/science.1223730.
6
Epigenetic changes in pediatric solid tumors: promising new targets.
Clin Cancer Res. 2012 May 15;18(10):2768-79. doi: 10.1158/1078-0432.CCR-11-1921.
7
Histone methylation: a dynamic mark in health, disease and inheritance.
Nat Rev Genet. 2012 Apr 3;13(5):343-57. doi: 10.1038/nrg3173.
8
A novel retinoblastoma therapy from genomic and epigenetic analyses.
Nature. 2012 Jan 11;481(7381):329-34. doi: 10.1038/nature10733.
9
Targeting the epigenome for treatment of cancer.
Oncogene. 2012 Aug 23;31(34):3827-44. doi: 10.1038/onc.2011.552. Epub 2011 Dec 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验